An observational study in Antiphospholipid Syndrome (APS), sponsored by University Hospital, Rouen. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by University Hospital, Rouen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Antiphospholipid Syndrome with a site in France — 11 open to participants now, 11 under way, 1 of them phase 3. Antiphospholipid Syndrome · France.
Among the 31 studies in Antiphospholipid Syndrome with a site in France, this one is the 10th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2019, is one of 17 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 28th registered.
121 studies on the registry are indexed under Antiphospholipid Syndrome; 52 are open to participants now.
Browse Antiphospholipid Syndrome studies →11 of the 31 studies in Antiphospholipid Syndrome with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18–70
CHU de Reims · Sites in France
Ages 65+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+ · Healthy volunteers
Chugai Pharmaceutical · Sites in France, United States, Australia and 17 more countries
Ages 18–85
Central Hospital, Nancy, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 38 Antiphospholipid Syndrome studies recruiting now, 14 (37%) set no upper age limit and 19 (50%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 156 across 50 observational studies indexed under Antiphospholipid Syndrome.
Median enrollment 102 across the 14 interventional studies, 310 across the 17 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 31 have an industry lead sponsor. The 10 most frequent:
University Hospital, Rouen is the lead sponsor of 418 studies on the registry; 106 are open to participants now.
University Hospital, Rouen has 2 studies filed under Antiphospholipid Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Antiphospholipid Syndrome with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT07178925University Hospital, RouenFollow-up Cohort of Patients With Antiphospholipid Syndrome | 2027-10-16 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Antiphospholipid Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Antiphospholipid syndrome (APLS) is a rare pathology characterized by the association of thrombotic (arterial, venous) or obstetric clinical manifestations and the persistent presence at least twelve weeks apart of antiphospholipid antibodies (APL). It is also accompanied by accelerated atherosclerosis responsible for an increased incidence of myocardial infarction, peripheral arterial disease and stroke explaining the high cardiovascular morbidity and mortality of these patients. APS can be isolated (primary) or integrated into an autoimmune pathology such as systemic lupus erythematosus (SLE), thus defining secondary APS. Current treatment is based on anticoagulation. Currently, epidemiological data that have evaluated recurrences have estimated a rate of 5% per year. However, these studies are old and due to the significant heterogeneity of patients included in this registry, it seems that these figures are not in agreement with clinical reality.
Furthermore, several new therapeutic developments have emerged in the field of anticoagulation with the marketing of DOACs, making the EUROPHOSPHOLIPIDE data questionable. Currently, there are no clinical studies to justify the use of DOACs in this indication, but several patients have received these drugs due to intolerance or refusal of vitamin K antagonists. The other therapeutic innovation compared to the data from the EUROPHOSPHOLIPIDE cohort is the increasing use of hydroxychloroquine in clinical practice in patients with primary APS. A trial (APLAQUINE) is currently underway in our department which aims to study the endothelial protective effect of this treatment in patients with primary APS.
This trial is a retrospective and prospective cohort epidemiological study whose primary objective is to determine the rate of thrombotic recurrence in our center. Secondary objectives are to determine the risk factors associated with recurrence, assess the safety of long-term treatment in this population, and evaluate the overall morbidity and mortality of this rare disease.
A better understanding of thrombotic recurrence is essential to calculate realistic population sizes for future therapeutic trials.
Patients monitored for Antiphospholipid Syndrome (APLS) in the internal medicine department
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The main objective of the research is to define the thrombotic recurrence rate in our cohort of patients followed for APS in the internal medicine department, to evaluate the complication rate associated with treatment, to search for risk factors associated with thrombotic recurrence and to define the mortality and morbidity rates of this patient population.
Thrombotic recurrence rate
The main objective of the research is to define the thrombotic recurrence rate in our cohort of patients followed for APS in the internal medicine department.
Time frame: Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease.
Complication rate
Evaluate the complication rate associated with treatment
Time frame: Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease.
Risk factors associated
Look for risk factors associated with thrombotic recurrence
Time frame: Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease.
Mortality rates
Evaluate the mortality rates of this patient population
Time frame: Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease.
Morbidity rates
Evaluate the morbidity rates of this patient population
Time frame: Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease.
Plan to share: No — The data provided will be the property of the sponsor and will be used solely for its own research activities.
No publications or documents are linked to this record.
Started Oct 2019 (actual). Primary completion is estimated for Oct 2027, 96 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2031 → Oct 2032.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.